Treatment choices for metastatic prostate cancer are complex and can involve men balancing survival versus quality of life. The present study aims to elicit patient preferences with respect to the attributes of treatments for metastatic prostate cancer through a discrete choice experiment (DCE) questionnaire. Men with recently diagnosed localized prostate cancer were asked to envisage that they had metastatic disease when completing a survey. As expected, men with prostate cancer placed considerable importance on gains in survival; however, avoiding side effects of treatment was also clearly important. Survival gains should be considered alongside side effects when discussing treatment options in metastatic disease.
Background
Within health care, it is common for patients to be asked to make trade-offs between different elements of treatment. Surgical procedures such as carotid endarterectomy require a patient to trade immediate risks of operative stroke against a potentially greater long-term reduction in risks of stroke. Conditions such as epilepsy, which sometimes entail a polypharmacy approach, require patients to decide whether additional efficacy benefits are worth the added side effect burden. Treatment for prostate cancer also requires patients to weigh different elements of effectiveness, possible prognoses, side effects and complications when making informed decisions regarding treatment. Patients' valuation of the efficacy and side effects regarding metastatic prostate cancer treatment have been examined, and so, a systematic analysis of these trade-offs may more fully illuminate the value of benefits associated with various prostate cancer therapies.
Several hormonal therapies are available for metastatic prostate cancer. One common approach to treatment is medical castration based on luteinizing hormone-releasing hormone (LHRH) agonists. LHRH agonists can be combined with non-steroidal anti-androgen treatments such as bicalutamide or the generic, flutamide, in what is described as combined androgen blockade (CAB) therapy. Some men opt for treatment with LHRH agonists alone, or alternatively choose other treatment strategies (such as surgical castration). For patients with prostate cancer, treatment with an LHRH agonist alone or in combination with bicalutamide or flutamide provides a non-surgical treatment option and can also be used as adjunctive therapy to surgery or radiation. These hormonal therapies may be differentiated according to efficacy (time to progression and/or survival), tolerability profile, cost, convenience (once-a-day dosing versus three times per day) and/or means of administration. 1 For example, CAB with bicalutamide is associated with a reduced risk of gastrointestinal problems versus CAB with flutamide, but may have a higher risk of haematuria. 2 However, it is assumed that these side effects are likely considered by the patient to be much less important than the potential for the treatment to prolong survival.
From the patient's perspective, optimal treatment for prostate cancer may be a function of the patient's willingness to make trade-offs between attributes such as efficacy and tolerability, and, in some countries, out-ofpocket cost. To optimize patient care, it is necessary for physicians and other health-care professionals to better understand the degree to which patients value outcomes associated with various treatment options (for example, hormonal treatment and watchful waiting). Such information can guide physicians in selecting treatments that will best meet the patient's needs and expectations, and improve his compliance and treatment outcomes.
To our knowledge, there are no published data specifically on patient preferences for hormonal therapy for metastatic prostate cancer. One study, however, did address the issue of preferences of healthy men for two different endocrine treatments for locally advanced prostate cancer. 3 Most participants preferred non-steroidal anti-androgen therapy compared with LHRH agonist therapy, primarily because of the relative side effect profiles. Sculpher et al. 4 report a discrete choice experiment (DCE) of patient preferences for conservative treatment in early-stage (non-metastatic) prostate cancer. This study explored the importance of diarrhoea, hot flushes, ability to maintain an erection, breast swelling or tenderness, physical energy, sex drive, life expectancy and out-of-pocket cost in 129 men with T stage 1 or 2 (non-metastatic) disease at diagnosis. Patients in the study were willing to trade life expectancy against improvements in the other attributes. All of the attributes were significant predictors of choice. The most important attributes for men included physical energy, breast swelling, diarrhoea and ability to maintain an erection (particularly for men o70 years). Results relating to willingness to pay (WTP) were not available for this study.
The objective of the current study was to assess patient preferences and WTP for various hormonal therapy regimens for metastatic prostate cancer, using a DCE.
Methods
This cross-sectional study was conducted with a sample of patients diagnosed with localized prostate cancer and with no previous hormonal therapy experience. Participants were asked to complete a computer-administered preference survey assessing preferences and WTP for various therapies. During this exercise, multiple therapy options were described by a set of specific attributes, which are known to be associated with the different therapy options. A pilot study was also conducted before full study launch to ensure survey administration techniques were optimal and patient comprehension was not a barrier to success.
Study measures
This study used a DCE, which is a form of survey methodology related to conjoint analysis. The DCE method is used to determine people's preferences for particular products or services and is rooted in economic theory. 5 The DCE method was chosen because this approach can be used to estimate the marginal value of the specific properties of different drugs (for example, risk of specific side effects) and combinations of properties that reflect drug profiles and drugs used in combination. It has been quite commonly used in health care to understand the value of different health technologies. [6] [7] [8] The DCE survey presented hypothetical treatments as treatment A and B and then asked participants to decide which they preferred. The treatments had different attributes, which were selected from a review of the literature and input from expert physicians. The attributes of each treatment were selected to be objective in nature, for example haematuria is a measurable finding and data exist regarding the risk of this with different treatments. Final attributes selected were as follows: gynaecomastia, haematuria, diarrhoea, convenience (in terms of dosing frequency), survival time and out-ofpocket cost as defined by a hypothetical monthly co-pay (see Box 1 for a description of the attributes and levels). The cost attribute was included to estimate WTP for different combinations of attribute levels. Gynaecomastia was included because it is a significant psychological issue for some men with prostate cancer. Estimates of the incidence of gynaecomastia vary from 13 to 22% for flutamide CAB, versus 8-13% for LHRH agonist. 9, 10 Diarrhoea was included because it is a relatively common side effect of flutamide. 2 Haematuria has been reported to occur significantly more frequently for metastatic patients on bicalutamide plus an LHRH agonist compared with patients on flutamide plus an LHRH agonist (Po0.007). 1 In developing the survey, we were concerned that we were presenting very bleak prospects to men who had only recently been diagnosed with prostate cancer. To minimize the potential impact of this, we explained carefully the nature of the survey and the fact that the treatments were for a more advanced stage of the disease than they themselves had. In addition, we told participants to assume that they could expect at least 36 months of survival and the different treatment choices may confer additional survival benefits. While this may be clinically unrealistic, for the DCE methodology, it was not a problem, as the study was designed to estimate the marginal value or benefits of Box 1 Description of the attributes presented to participants Length of life 'Some drug treatments can improve your overall length of life. Please imagine that you have been told that one in two (50%) people with metastatic stage cancer (cancer that has spread to other parts of the body) die within a 3-year timeframe. If certain drug treatments are taken your overall length of life could increase by the numbers below'. Cost 'The amount of money you have to pay per month for this drug treatment, regardless of your insurance coverage. Think about how much value each drug treatment has to you and decide whether you would be willing to pay this amount per month.' Haematuria 'Taking medication for prostate cancer can cause you to pass blood in your urine (referred to as haematuria). This is generally a mild condition but it can cause people to worry.' Diarrhoea 'Consists of frequent stools where the stool is loose, soft and watery. You may have a crampy pain in your stomach. Diarrhoea can be bothersome and interfere with your normal day to day activities.' Gynaecomastia 'The enlargement of the male breast. It consists of the growth of a flat pad of tissue beneath the nipple and usually occurs in both breasts at the same time. This condition can be temporary and the breast can return to normal when drug treatment is stopped. Breast enlargement can be noticeable. Sometimes it can also be painful.' Convenience 'The products are all pills that are taken by mouth every day. Please note that you would also receive injections in addition to these pills regardless of which treatment you chose.'
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DCE questionnaire
The attributes and levels were combined into choice sets using a fractional factorial orthogonal design. The choice sets were presented as pairs and participants were asked to decide whether they preferred treatment A or B ( Figure 1 ). No opt-out option (that is, a choice of 'neither option') was included because this was considered unrepresentative of real life. Two questions were included as a consistency check to ensure participants understood the task. Participants were provided with a laminated sheet that described each attribute in more detail. They were asked to read each of these before starting the study and the laminates were available throughout for reference. The DCE questionnaire was combined with questions regarding socio-demographics and clinical status of participants. The computerized preference survey was completed onscreen using a laptop computer at one study visit before seeing the clinician. A pilot study of the computerized preference survey was conducted to test the reader comprehension of the survey. Pilot study participants (matching main study entry criteria) completed the survey and then participated in a cognitive debriefing interview to assess the clarity and interpretation of the survey questions and response options. Revisions to the survey were made based on the pilot test. Full Institutional Review Board approval was granted for this study.
Study sample
The study was conducted at three sites in the United States. Participants were recruited by reviewing their medical charts, first targeting those scheduled for appointments over the course of the study. Those meeting the eligibility criteria based on chart review were contacted and screened to confirm eligibility. Participants had to meet all of the following criteria to be eligible for the study: diagnosis of localized prostate cancer; 18-75 years old; no previous hormonal therapy; had not turned down hormonal therapy as a treatment option in the past; elevated prostate-specific antigen (PSA) level (44 ng/ml before any treatment) or rising PSA level; ability to read and understand English; willing and able to give informed consent before study entry; no concurrent medical or psychiatric condition that, in the investigator's opinion, might preclude participation in this study; no cognitive or other type of impairment (for example, visual) that would interfere with completing a self-administered computer-based, questionnaire; and no current participation in a clinical trial for any investigational or approved treatments for 
diagnosed patients. In the survey, they were asked to imagine that they had metastatic disease. The survey was considered to be inappropriate for men with metastatic disease to complete as it might be seen to interfere with necessary conversations between physician and patient regarding treatment options.
Analysis
The DCE data were analysed using the logit procedure in the statistical analysis package SAS. This analysis was designed to understand the relative importance of each of the attributes and the extent to which people are willing to trade-off one against another. The underlying assumptions regarding the form of the utility function in the analysis are detailed in Box 2. From this analysis, WTP for all attributes was estimated by taking the marginal rates of substitution between the 'monthly cost of the drug' attribute and the remaining attributes.
Distinct levels for each attribute were identified for each of the three main treatment options (bicalutamide plus LHRH agonist, flutamide plus LHRH agonist and LHRH agonist alone). Product efficacy and safety profiles were estimated using data obtained from published clinical trials. 1, 2, 11 Estimates of survival related to androgen suppression and CAB from the literature vary widely. [12] [13] [14] The Prostate Cancer Trialists' Collaborative Group 11 reports a meta-analysis of trials of androgen suppression versus CAB and concludes that flutamide plus an LHRH agonist confers a 2% improvement in survival over androgen suppression alone. 11 The PCTG analysis demonstrated that, when analysed by steroidal versus non-steroidal anti-androgen, CAB with a steroidal anti-androgen showed a 13% increase in risk of death versus LHRH agonist alone and CAB with a nonsteroidal anti-androgen showed an 8% decrease in the risk of death versus LHRH agonist alone. Schellhammer 2 reported that median survival for bicalutamide plus an LHRH agonist was 180 weeks (41.5 months) and survival for flutamide plus an LHRH agonist was 148 weeks (34.2 months). The data from Schellhammer 2 were used to make direct comparisons between CAB with flutamide and CAB with bicalutamide. Survival on an LHRH agonist alone was estimated by reducing the survival on flutamide (from Schellhammer) by 2%. The three product profiles (bicalutamide plus LHRH agonist, flutamide plus LHRH agonist and LHRH agonist alone) are presented in Table 1 . The overall preference for each product profile was explored by estimating the overall WTP amount for each product. This was determined by using the WTP values from the analysis matched with the profiles for each product. The description of the length-of-life attribute in the DCE survey required participants to imagine that they had a 50% chance of surviving 3 years, which may be clinically unrealistic. However, in estimating the WTP for different products, it is important to recall that the values from the choice analysis are marginal values, which is the amount people are willing to pay for a unit improvement in an attribute. This value is independent of the base case; to explore more clinically realistic choices, we used the same marginal values for unit shifts in attributes, with a more clinically realistic median survival as the base case. The most suitable base case we believe is treatment with an LHRH agonist alone. The analysis determines an incremental WTP for flutamide and bicalutamide plus an LHRH agonist over treatment with an LHRH agonist alone (Table 1) .
Results
A total of 65 participants completed the main survey. The demographics (Table 2 ) indicate the high proportion of white Caucasian men, most of who lived with their partner. Initially, there were 20 discrete choices per respondent, which resulted in 1300 observations in total. There were no missing responses to choice questions, as the data-capture software did not allow for a nonresponse and all participants completed the survey. Discrete choice numbers 9 and 11 were removed for all respondents before analysis, as consistency checks. A data check after the first 30 patients had completed the study revealed that the attribute coefficients were all in the anticipated direction and only a small proportion of participants failed the consistency check. Ninety-one per cent (59/65) of participants answered both consistency checks (questions 9 and 11) correctly; this result demonstrates a good level of understanding among study respondents regarding the nature of the DCE exercise. Table 3 provides the results of the logit model and the WTP results with 95% confidence intervals (CIs). All the attribute coefficients have the expected sign (all negative apart from length of life, which is positive) and are all significant predictors of choice (as shown by the P-values). All of the attributes were independently important to participants. Participants were willing to pay the most for gains in survival.
To gain an additional month of life, patients were willing to pay $80.49 per month or $965.88 per year. To reduce their chance of side effects by 1%, patients were willing to pay $7.14 for a reduction in haematuria, $5.95 for a reduction in diarrhoea and $6.30 for a reduction in gynaecomastia per month. In addition, participants were willing to pay $102.02 to change from needing to take two pills three times a day to taking only one pill per day.
Box 2 The underlying assumptions regarding the form of the utility function used in analysis of data from the discrete choice experiment
The choice experiment assumes the following form of the utility function: DC ¼ a 1 Dlength of life+a 2 Dhaematuria+a 3 Ddiarrhoea+a 4 Dgynaecomastia+a 5 Dconvenience+a 7 DCost+e+ u Where, DC is the change in utility in moving from option A to option B, e and u are the unobservable error terms, where e is the error term due to differences among observations and u is the error term due to difference amongst respondents (Manski, 1977 
Discussion
This study explored the preferences of patients with prostate cancer regarding hormonal treatments for Patient preferences for prostate cancer hormonal therapy A Lloyd et al metastatic disease. The study of 65 patients who had been recently diagnosed with localized prostate cancer revealed that maximizing survival and minimizing any risk of side effects and inconvenience from treatment are all significant issues. It might have been predicted that participants would seek to maximize their survival chances rather than being concerned about side effects or convenience. It is worth noting, however, that even among newly diagnosed patients who may still be coming to terms with the prospect of cancer, relatively minor side effects from treatment such as diarrhoea and gynaecomastia are a significant concern for them. The DCE survey sought to quantify the value that participants place on different aspects of treatment by estimating WTP for incremental improvements in survival, convenience and reductions in the chance of side effects. The use of WTP provides a common scale, that is dollars, with which the relative importance of different attributes can be compared; this common metric of money has the intrinsic benefit of being something that everyone can understand. The WTP values can also be used to model participants' preferences for different product profiles. It was clear from the results that improving survival was the most important issue for participants in the survey, in that they were willing to pay the highest amount of money for an improvement in this attribute. The three side effect attributes -gynaecomastia, diarrhoea and haematuria -were broadly similar in their importance. Finally, the dosing frequency was also a significant issue for men and they were WTP approximately $100 per month to improve convenience from two pills three times a day to one pill per day.
The WTP data were used to understand patients' preferences for different treatments for metastatic prostate cancer. The preferences for bicalutamide plus an LHRH agonist and flutamide plus an LHRH agonist compared with an LHRH agonist alone were modelled using the available preference data. This exercise showed that the men were willing to pay considerably more for bicalutamide plus an LHRH agonist. The WTP values are entirely dependent on the assumptions made regarding the product profiles. If new data emerge suggesting that the survival benefits of CAB with bicalutamide are not as great as suggested by Schellhammer 2 , then the WTP values could be revised. In addition, if a new product emerged with a different profile, then its perceived benefits for men with prostate cancer could be easily estimated using the information in Table 1 .
This study demonstrated that men with prostate cancer place considerable importance on the avoidance of side effects in the treatment of metastatic disease when compared with gains in survival ( Table 4 ). The data suggest that survival gains should be considered alongside side effects when discussing treatment decisions in metastatic disease. Participants also placed considerable importance on the avoidance of onerous treatment regimens that necessitate taking tablets three times a day. These data echo the findings of Jenkins et al., 3 who asked healthy men to consider the side effects of treatments for locally advanced prostate cancer. Here men's concerns were focused on the risk of fractures and loss of physical strength rather than impotence or gynaecomastia. The authors conclude that men have a strong preference for non-steroidal anti-androgen therapy rather than LHRH agonist therapy. The data also indicate that participants were willing to trade survival gains against improvements in side effects. The data indicate that, for example, if we considered a risk of mild diarrhoea to be 25%, then participants would be willing to trade 1.848 months of life to avoid this risk. Sculpher et al. 4 report that patients in their study were willing to trade 1.8 months of survival to avoid mild diarrhoea.
There are some notable limitations to this study that should be considered. This study was designed to elicit preferences for the treatment of metastatic prostate cancer, but the participants in the study did not themselves have metastatic disease. The participants in the study were patients with localized prostate cancer that had been recently diagnosed. In the survey, they were asked to imagine that they had metastatic disease and that they only had a 50% chance of surviving 3 years. This was done because it was thought that it would be inappropriate to ask patients with metastatic disease to make these treatment choices. In particular, it was felt that presenting such patients with very specific survival data in a theoretical scenario would be difficult both ethically and practically; by asking participants to imagine they have a more advanced form of prostate cancer, we could avoid these issues. We believe that this represents an appropriate and practical method for capturing preference data for metastatic disease. It is clear that the attribute describing survival gains is the most important attribute for participants. Because of its importance, it may have effectively swamped people's choices, but the analyses indicate that participants were in fact willing to trade against survival. Therefore, even in the context of such an important attribute, it was possible to understand the importance that people placed on other issues such as side effects and convenience. However, it is not possible to include attributes describing every aspect of prostate cancer treatment. There may be factors that are important to some men that we failed to include. In principle, the WTP amounts should not change as a result of adding additional elements to the survey; so the findings for this survey should be robust for the attributes we included.
Our results do not represent individual preferences; rather we have preference data in an aggregate form. Therefore, these results will not of course be true for every patient, and variability will exist. Knowledge of these results can serve as a starting point for physicians when accounting for individual patient preferences during the discussion of treatment options. Highlighting these data may help patients as they explore their own preferences and make difficult decisions regarding their treatment.
